Michael Artinger, PhD

Michael Artinger, PhD
Michael Artinger, PhD, Executive Vice President and Managing Director VIC Colorado Branch, has spent his career transforming innovation into commercial opportunity. He has worked closely with universities and inventors across the nation to recognize the potential of their discoveries and has deep domain expertise across multiple verticals, including therapeutics, vaccines, medical devices, diagnostics and information technology/software. Dr. Artinger earned his Doctorate degree in Biology focusing on Developmental and Cell Biology, as well as his Baccalaureate degree in Applied Ecology from the University of California at Irvine.
Find me on:

Recent Posts

The Emerging Remote Workplace: Digital Best Practices for Investor Groups

As the recent pandemic has made all too clear, organizations need to proactively prepare for the realities of a dispersed workforce, which is especially true for investor groups such as venture capital and private...

White Paper: New Paradigms of Life Science Investing

For decades, only venture capital (VC) firms, and very rarely, angels were able to invest in start-up companies developing life science—therapeutics, medical devices, diagnostics, and related—innovation. Anyone doing so...

White Paper: Accessing Innovation Directly From The Source - The Growing Trend Of Venture Capital Company Formation

Historically, innovative technologies discovered at universities, institutes and national labs have had two primary paths towards commercialization: (1) licensing to a large, pre-existing company; or, (2) licensing to...


VIC Tech Announces New Class of Fellows
Our Life Science and Healthcare Future
White Paper
Portfolio Diversification in Times of Market Volatility
Inside the Office of Technology Commercialization at the University of Kentucky with Holly Clark, PhD, Senior Commercialization Manager
Seven Reasons Venture Capital-Stage Companies Should Become Part of Your Investment Portfolio
White Paper
Investing in Medical Devices & Diagnostics – Industry Trends and Investor Activity
Solenic Medical, Inc. Announces $5.1M Series A Funding Round Led by Johnson & Johnson Innovation – JJDC, Inc.
VIC Fellows Spotlight: Matthew Leming, PhD
From The Corner Office
From the Corner Office: Michael Artinger, PhD – CEO of Solaris Vaccines, Inc.